Healio3h
Adding anifrolumab superior to standard therapy alone, maintains remission in lupus
Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...
pharmaphorum3y
FDA approves AZ's anifrolumab, ending 10-year lupus drug drought
Anifrolumab was all-but written off in 2018 after failing the phase 3 TULIP-1 trial, but bounced back with positive data from a second study – TULIP-2 – that has proved sufficient for the FDA ...
pharmaphorum8d
UCB, Biogen lupus drug scores in phase 3 trial
UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus ... GSK's Benlysta (belimumab), AstraZeneca's Saphnelo (anifrolumab), and Otsuka's Lupkynis (voclosporin).
Medical Xpress28d
Drug can stave off organ damage from lupus, research reveals
Anifrolumab (brand name Saphnelo) reduced the risk of long-term organ damage progression by about 60% in patients with moderately to severely active lupus, researchers reported in a new study ...
Monthly Prescribing Reference26d
Anifrolumab Tied to Less Organ Damage for Patients With Lupus
The likelihood of experiencing an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index within 208 weeks was lower for patients in the ...